From the Northwestern University, Chicago, Illinois (Myers); University of California, San Francisco, San Francisco, California (Chang); Kaiser Permanente, Walnut Creek, California (Shorstein); Scripps Clinic Medical Group, La Jolla, California (Mah); Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, Salt Lake City, Utah (Mamalis); Stein Eye Institute and Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California (Miller).
J Cataract Refract Surg. 2023 Oct 1;49(10):1068-1070. doi: 10.1097/j.jcrs.0000000000001237.
Moxifloxacin solution is frequently injected at the conclusion of cataract surgery for endophthalmitis prophylaxis. 2 different concentrations are most commonly available in the United States for intracameral (IC) use: 0.5% (5 mg/mL) and 0.1% (1 mg/mL). The recommended volume to be injected is different for the 2 concentrations, and incorrect dosing can increase the risk of toxic anterior segment syndrome or endophthalmitis. In addition, the U.S. Food and Drug Administration recently published an alert regarding potential adverse events associated with intraocular compounded moxifloxacin. This clinical advisory reviews the optimal dosing of IC moxifloxacin based on current evidence.
莫西沙星溶液常用于白内障手术后的眼内炎预防。在美国，最常用于眼内（IC）注射的有两种不同浓度：0.5%（5mg/ml）和 0.1%（1mg/ml）。两种浓度的推荐注射量不同，剂量错误会增加前节毒性综合征或眼内炎的风险。此外，美国食品和药物管理局最近发布了一则关于与眼内配制莫西沙星相关的潜在不良事件的警告。本临床咨询根据现有证据回顾了 IC 莫西沙星的最佳剂量。
